Status:
COMPLETED
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
25-60 years
Phase:
NA
Brief Summary
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine. The methods differed in the type and frequenc...
Eligibility Criteria
Inclusion
- 1- Body mass index -calculated as weight in kilograms divided by the square of height in meters- ≥30 and \<40 kg/m2.
- 2- Eligibility to be prescribed sibutramine, following the eligibility requirements listed in the US Package Insert
- 3- Willingness and ability to comply with study related procedures
- 4- Access to Internet and email
Exclusion
- Uncontrolled blood pressure (defined as ≥140/90 mmHg), diabetes, coronary heart disease, chronic congestive heart failure, stroke, significant metabolic, hepatic or renal disease, current malignancy, gastric bypass surgery or had a weight loss ≥10%, participated in a structured weight loss program, or had taken weight loss agents during the past 6 months. Women were excluded if pregnant or breastfeeding; women of childbearing potential had to use adequate contraception.
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00471172
Start Date
August 1 2004
End Date
May 1 2005
Last Update
September 15 2008
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States
2
Pfizer Investigational Site
Clearwater, Florida, United States
3
Pfizer Investigational Site
Kissimmee, Florida, United States
4
Pfizer Investigational Site
Pembroke Pines, Florida, United States